Fiona H. Marshall
President, Biomedical ResearchNovartis
PharmaceuticalsView Profile →EVP and President, BioPharmaceuticals Business Unit · AstraZeneca
Ruud Dobber leads AstraZeneca’s BioPharmaceuticals Business Unit. His career spans immunology research and commercial leadership across Asia Pacific, Europe and North America.
Last reviewed: Nov 16, 2026
Ruud Dobber leads AstraZeneca’s BioPharmaceuticals Business Unit. His career spans immunology research and commercial leadership across Asia Pacific, Europe and North America.
Dobber’s academic background includes a master’s degree from Utrecht University and an immunology doctorate from Leiden. He began his career as a research scientist working on immunology and ageing, before moving into pharmaceutical management.
He joined Astra in 1997. His subsequent regional leadership assignments included Asia Pacific and Europe, the Middle East and Africa. In December 2013, he also took interim responsibility for global product and portfolio strategy alongside his European commercial office.
Dobber became executive vice president for Europe in January 2013 and took the North America portfolio in August 2016. Those appointments preceded the company’s January 2019 reorganization, which placed him in charge of the BioPharmaceuticals commercial unit.
His present remit combines product strategy with commercial delivery across cardiovascular, renal and metabolic medicines, respiratory and immunology, and vaccines and immune therapies. His wider industry experience includes service with EFPIA and chairmanship of PhRMA’s Asia division. He joined Almirall’s board as an independent director on June 18, 2021. His subsequent committee work there included nominations and remuneration from May 2022 and governance from May 2024.
Ph.D. — Leiden University — Immunology.
Master of Science — Utrecht University.